Codexis, Inc. (NASDAQ:CDXS) had its Buy rating reiterated by HC Wainwright with a $16.50 price target

Analyst Ratings For Codexis, Inc. (NASDAQ:CDXS)

Story continues below

Today, HC Wainwright reiterated its Buy rating on Codexis, Inc. (NASDAQ:CDXS) with a price target of $16.50.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Codexis, Inc. (NASDAQ:CDXS) is Buy with a consensus target price of $19.8750 per share, a potential 23.29% upside.

Some recent analyst ratings include

  • 1/14/2019-Codexis, Inc. (NASDAQ:CDXS) had its Buy rating reiterated by HC Wainwright with a $16.50 price target
  • 6/19/2018-Codexis, Inc. (NASDAQ:CDXS) has coverage initiated with a Outperform rating and $18.00 price target
  • 1/26/2017-Codexis, Inc. (NASDAQ:CDXS) gets downgraded to Equal Weight by First Analysis with a price target of $5.50
  • On 12/28/2018 Thomas R Baruch, Director, sold 25,000 with an average share price of $16.03 per share and the total transaction amounting to $400,750.00.
  • On 12/26/2018 Dennis P Wolf, Director, sold 9,000 with an average share price of $15.83 per share and the total transaction amounting to $142,470.00.
  • On 12/20/2018 Patrick Y Yang, Director, sold 50,000 with an average share price of $18.52 per share and the total transaction amounting to $926,000.00.
  • On 12/7/2018 John J Nicols, Insider, sold 43,812 with an average share price of $21.78 per share and the total transaction amounting to $954,225.36.
  • On 11/13/2018 James Lalonde, SVP, sold 13,453 with an average share price of $15.40 per share and the total transaction amounting to $207,176.20.
  • On 10/3/2018 Gordon Sangster, CFO, sold 80,000 with an average share price of $16.94 per share and the total transaction amounting to $1,355,200.00.
  • On 9/28/2018 John J Nicols, Insider, sold 80,000 with an average share price of $17.57 per share and the total transaction amounting to $1,405,600.00.

About Codexis, Inc. (NASDAQ:CDXS)
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Recent Trading Activity for Codexis, Inc. (NASDAQ:CDXS)
Shares of Codexis, Inc. closed the previous trading session at 16.12 −0.080 0.49% with 15.91 shares trading hands.

An ad to help with our costs